AZD7325

DRUG12 trials

Sponsors

AstraZeneca, University of California, Los Angeles

Conditions

AbsorptionAnxietyAnxiety DisordersAutism Spectrum DisorderDistributionExcretionHealthyHealthy Volunteer

Phase 1

AZD7325 Multiple Ascending Dose Study

CompletedNCT00681915

AstraZenecaHealthy Volunteer

Start: 2008-03-31End: 2008-07-31Target: 48Updated: 2010-12-09

Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325

CompletedNCT00681720

AstraZenecaAnxiety

Start: 2008-02-29End: 2008-07-31Updated: 2008-08-21

A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator.

CompletedNCT00720421

AstraZenecaHealthy Volunteer

Start: 2008-06-30End: 2008-08-31Target: 16Updated: 2010-12-10

AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects

CompletedNCT00769899

AstraZenecaHealthy Volunteer

Start: 2008-10-31End: 2009-03-31Updated: 2009-03-18

Determine the Effect of Multiple Doses of AZD7325, CYP Study

CompletedNCT00790114

AstraZenecaHealthy Volunteer

Start: 2008-07-31End: 2008-09-30Updated: 2008-11-13

Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects

SuspendedNCT00901290

AstraZenecaPharmacokinetics

Start: 2009-05-31End: 2009-09-30Target: 56Updated: 2010-12-10

Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users

CompletedNCT00902772

AstraZenecaRecreational CNS Depressant Use

Start: 2009-05-31End: 2009-09-30Target: 100Updated: 2009-09-23

Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration

SuspendedNCT00940641

AstraZenecaAbsorption, Distribution, Excretion +1

Start: 2009-08-31End: 2009-10-31Target: 8Updated: 2011-01-24

AZD7325 Japan Multiple Ascending Dose (MAD) Study

TerminatedNCT00945425

AstraZenecaHealthy

Start: 2009-07-31End: 2009-11-30Target: 48Updated: 2011-02-16

Phase 2

Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

CompletedNCT00807937

AstraZenecaAnxiety Disorders

Start: 2008-12-31End: 2009-05-31Updated: 2010-10-08

AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

CompletedNCT00808249

AstraZenecaAnxiety Disorders

Start: 2008-12-31End: 2009-05-31Updated: 2011-06-20

Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial

CompletedNCT01966679

University of California, Los AngelesAutism Spectrum Disorder

Start: 2013-10-31End: 2015-07-31Updated: 2015-10-22